1. Imugene (IMU) - PH's first child. B-Cell technology platform has been de-risked. Very undervalued at current MC. Drug supply deals with Merck KGaA, Pfizer and Merck & Co. Collaborations with Eureka Therapeutics and Celularity. The closest of the three to signing a deal with big pharma. World class management and SAB.
2. Chimeric Therapeutics (CHM) - Early stage. High risk. Has the potential to be bigger and better than IMU. World class management and SAB.
3. Radiopharm Theranostics (RAD) - Not invested and not interested. PH has enough of my $$$ invested in his companies...hahaha
Paul Hopper IP opportunists CHM VS RAD, page-2
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
-0.001(2.94%) |
Mkt cap ! $14.63M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.8¢ | 1.7¢ | $29.99K | 1.767M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 2101609 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 178844 | 2 |
View Market Depth
| Last trade - 13.32pm 22/08/2024 (20 minute delay) ? |
| CHM (ASX) Chart |